Preclinical evidence shows that obese mice exhibit elevated PPARG expression, with PPARG agonists worsening hepatic steatosis; conversely, genetic deletion or downregulation of PPARG protects against steatosis (Gao et al., 2016; Moran et al., 2011). Here, PPARG is linked to fatty liver disease.